Q32 Bio To Reveal Phase 1 Clinical Trial Results For Tissue-Targeted Complement Inhibitor ADX-097 At The American Society Of Nephrology Kidney Week 2024
Q32 Bio To Reveal Phase 1 Clinical Trial Results For Tissue-Targeted Complement Inhibitor ADX-097 At The American Society Of Nephrology Kidney Week 2024
Q32 Bio將在2024年美國腎臟病學會腎週上公佈組織靶向補體抑制劑ADX-097的1期臨床試驗結果
-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued clinical advancement of ADX-097 --
-- 海報展示將突出ADX-097在健康志願者中完成的第一階段人體首次劑量遞增臨床試驗數據；結果支持第2階段劑量選擇和繼續推進ADX-097的臨床 --
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間